Who We Are
Immunis.AI is a privately held immunogenomic ‘liquid biopsy’ platform company focused on early detection of cancer and other diseases, at the point of immune-escape, when there is the best opportunity for cure.
Our patented Intelligentia™ platform combines the power of the immune defense system, RNAseq technology and machine learning for the development of disease-specific algorithms.
Our proprietary approach compares the differential gene expression patterns from two immune cells, using the patient as the control, normalizing and enhancing the signal of the underlying pathology to provide individualized diagnostic, prognostic, therapeutic response and disease monitoring assessment.
We will improve the human condition globally by combining the power of the immune system and our proprietary platform, to deliver actionable medical information.
We will empower patients with deeper insights into their health and importantly, the opportunity for early diagnosis, when there is the greatest chance for cure.
We will deliver novel tests on our immunogenomics platform which will save lives, enrich quality of life and provide peace of mind to patients and their loved ones.